Adverse events of benralizumab in moderate to severe eosinophilic asthma: A meta-analysis

BACKGROUND: Benralizumab, a humanized, anti-interleukin-5 (anti-IL-5) receptor α monoclonal antibody that directly and rapidly depletes eosinophils, has shown significant efficacy in reducing asthma exacerbations and improving lung function in moderate to severe eosinophilic asthma patients. However...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wanshu, Ma, Xuesu, Zhou, Weikang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709166/
https://www.ncbi.nlm.nih.gov/pubmed/31145343
http://dx.doi.org/10.1097/MD.0000000000015868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709166/
https://www.ncbi.nlm.nih.gov/pubmed/31145343
http://dx.doi.org/10.1097/MD.0000000000015868

Ejemplares similares